CIK 0001175680 · Non-accelerated filer<br>Smaller reporting company
CytoDyn Inc.
Sign in to watch- Ticker
- CYDY
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- May 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 753056237
- Phone
- 360-980-8524
- Business address
- 1111 MAIN STREET, SUITE 660, VANCOUVER, WA, 98660
- Former names
- CYTODYN INC, REXRAY CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-12-23 | Welch David F Director | Grant or award · Warrants (right to buy) | +819,672 | 819,672 | ||
| 2019-12-19 | Pourhassan Nader President & CEO | Grant or award · Stock Option (right to buy) | +2,000,000 | 2,000,000 | ||
| 2019-12-19 | Pourhassan Nader President & CEO | Grant or award · Warrant (right to buy) | +2,000,000 | 2,000,000 | ||
| 2019-12-19 | Mulholland Michael D. See Remarks | Grant or award · Stock Option (right to buy) | +700,000 | 700,000 | ||
| 2019-12-19 | Ray Nitya G. See Remarks | Grant or award · Stock Option (right to buy) | +600,000 | 600,000 | ||
| 2019-12-19 | Klump Michael A Director | Grant or award · Stock Option (right to buy) | +750,000 | 750,000 | ||
| 2019-12-19 | Naydenov Jordan G Director | Grant or award · Stock Option (right to buy) | +750,000 | 750,000 | ||
| 2019-12-19 | Welch David F Director | Grant or award · Stock Option (right to buy) | +750,000 | 750,000 | ||
| 2019-12-19 | Kelly Scott A. Director | Grant or award · Stock Option (right to buy) | +1,250,000 | 1,250,000 | ||
| 2019-12-13 | Naydenov Jordan G Director | Grant or award | +833,333 | 6,137,823 | ||
| 2019-12-13 | Naydenov Jordan G Director | Grant or award · Warrants (right to buy) | +625,000 | 625,000 | ||
| 2019-11-13 | Eastwood Craig S. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2019-10-08 | Klump Michael A Director | Returned to the company · Convertible Promissory Note | −500,000 | |||
| 2019-10-08 | Klump Michael A Director | Grant or award · Convertible Promissory Note | +537,397 | |||
| 2019-10-08 | Klump Michael A Director | Grant or award · Warrant (Right to Buy) | +500,000 | 500,000 | ||
| 2019-10-07 | Ray Nitya G. See Remarks | Grant or award · Stock Options (right to buy) | +187,500 | 187,500 | ||
| 2019-10-07 | Mulholland Michael D. CFO, Treasurer and Secretary | Grant or award · Stock Options (right to buy) | +187,500 | 187,500 | ||
| 2019-10-07 | Welch David F Director | Grant or award · Stock Options (right to buy) | +187,500 | 187,500 | ||
| 2019-10-07 | Welch David F Director | Grant or award · Stock Options (right to buy) | −187,500 | 187,500 | ||
| 2019-10-07 | Pourhassan Nader President & CEO | Grant or award · Stock Options (right to buy) | +375,000 | 375,000 |
Page 17 of 33 · 652 trades